Multicomponent-based analyses of ACS-patient-derived extracellular vesicles as likely tools for tailored interventional approaches

基于多组分分析的ACS患者来源细胞外囊泡有望成为制定个性化干预方案的工具

阅读:10
作者:Saveria Femminò ,Alessandro Sarcinella ,Alberto Grosso ,Francesca Mensitieri ,Ovidio De Filippo ,Francesco Bruno ,Albino Coglianese ,Marta Tapparo ,Edoardo Pace ,Sharad Kholia ,Stefania Bruno ,Rosa Ciullo ,Fabrizio Buffolo ,Giovanni Camussi ,Gaetano Maria De Ferrari ,Fabrizio Dal Piaz ,Fabrizio D'Ascenzo ,Maria Felice Brizzi

Abstract

Reliable predictive biomarkers to reduce unnecessary coronary angiograms (CAGs) in non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina (UA) patients displaying high-risk features are still lacking. Here, we show that profiling patient-derived circulating extracellular vesicles (EVs) can not only improve their risk stratification but also reduce unnecessary CAGs. Analysis of EVs and their miR cargo revealed that CD62p+EVs enriched in miR-130a-3p correlated with the absence of non-critical coronary artery disease (CAD). Proteomic analysis identified nine proteins differentially enriched in patients with or without critical-CAD (NO CAD), irrespective of their diagnosis. Multivariate analysis identified miR-130a-3p (odds ratio [OR]:0.35 [0.19-0.67]), phospholipid transfer protein (OR 0.96 [0.94-0.98]), and subunit beta of mitochondrial trifunctional enzyme (OR:0.96 [0.94-0.98]) as predictors of NO CAD. Furthermore, EV-miR-130a-3p enrichment predicted the absence of multivessel disease (OR:0.46 [0.23-0.90]). These findings establish EV profiling as a valuable tool for stratifying and optimizing the clinical management of patients with acute coronary syndrome.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。